Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,397.59
(
-0.84%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 59232

Wednesday, 05/14/2008 2:29:29 PM

Wednesday, May 14, 2008 2:29:29 PM

Post# of 257579
MNTA 2008-2009 News Flow

[Updated for today’s appellate
court ruling on Lovenox patent.]

3Q08:
Resubmit Lovenox ANDA with immunogenicity info requested by FDA.

2H08:
M118 phase-2a data in stable angina presented at medical conference.

2H08:
Start M118 phase-2b trial in PCI.

4Q08/1Q09:
FDA action on Lovenox ANDA (assuming resubmission of ANDA in 3Q08).

2H08/1H09:
Submit ANDA for generic Copaxone (no formal guidance from MNTA).

2H08/1H09:
Ink partnership deal for M118.

2H08/1H09:
Announcements re FoB program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today